Everything
Merck's Heart Failure Drug Misses Trial Goals
Merck and Co. said Friday its heart failure treatment rolofylline missed its goals in a trial, failing to improve patient symptoms compared with a placebo.
Comments on 6Minutes.com.au
Home | Contact Us | Advertise | About Us | Privacy Policy | News Archive Medicine Politics Practice Ideas Other stuff Jobs Search Latest Comments Doesn't this contradict the evidence that ACE inhibitors and beta
SILANES
Pharmaceuticals, Namely, Injectable Solutions, Tablets, Pills and Capsules For Adults and Children, Oral Suspension, Medicated Syrup and Ointment, All For Treatment As a Cough Suppressant, and Expectorant, Activity Against Anaerobic Bacteria, Trichomona Vaginalis, Entamoeba Histolytica, and Giardia
doi:10.1016/S0140-6736(05)61858-2
THE LANCET Vol 350 • July 12th, 1997 147 4 Lan KKG, Simon R, Halperin M. Stochastically curtailed tests in long-term clinical trials. Commun Stat 1983; 1: 207–19. Ibopamine and survival in severe congestive heart failure: PRIME II SIR—Those conducting clinical trials in human beings have an
Adverse event with first-dose perindopril in congestive heart failure : The Lancet
Adverse event with first-dose perindopril in congestive heart failure. By - Kennedy R Lees, John L Reid
Angiotensin-receptor blockers as cardioprotective drug therapy — Irish Medical Times
February 4, 2012 Home Contact Us About Us Subscribe Advertising Terms of Use Privacy Policy Sitemap RSS Feeds Irish Medical Times News Opinion Features Editorial Letters Blogs Clinical Times MIMS Ireland Lifestyle Jobs Events Small ads You are here: Home / Clinical Times / Cardiovascular /
Combination therapy 'does not cut cardiovascular risk' - Healthcare Republic News
Combination therapy 'does not cut cardiovascular risk' details online - Primary care news: Medical and Primary Care articles for UK Doctors, GPs, Pharmacists and Prescribing Nurses - Healthcare Republic
PERFAN
Pharmaceuticals For the Treatment of Heart Disease
doi:10.1016/S0140-6736(05)77766-7
1732 THE LANCET • Vol 351 • June 6, 1998 CORRESPONDENCE novo nitrates) compared with a nitratebased regimen (intravenously coinfused glyceryl trinitrate [2·5–10·0 g/min] and N-acetylcysteine) in 69 consecutively admitted patients with non-ischaemic acute cardiogenic oedema and mean initial
doi:10.1016/S0140-6736(02)11611-4
For personal use. Only reproduce with permission from The Lancet Publishing Group. 5 Task Force for the Diagnosis and Treatment of Chronic Heart Failure ESoC, Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527–60. 6 Cleland JGF,
Refine by Content Type:
Refine by Source:
- www.thelancet.com (23)
- download.thelancet.com (17)
- healthcare.zibb.com (2)
- www.6minutes.com.au (2)
- www.dddmag.com (1)
- www.healthcarerepublic.com (1)
- www.imt.ie (1)
